Latest Announcements

Permanent Magnets Ltd has announced its unaudited financial results for Q1FY27, with revenue from operations growing by 19% YoY and operating margins remaining healthy.

EPack Prefab Technologies Limited held a conference call to discuss its Q1 FY27 earnings, with a revenue growth of 25% and a 150% increase in the order book. The company received significant orders from a renewable company and an automobile company, and maintained its track record for quarter-to-quarter growth.

Deepak Fertilizers and Petrochemicals Corporation Limited has informed the Exchange about the Management Transcript of Q1 FY 2027 Earnings Conference Call, which will be made available on the company's website.

Standard Engineering Technology Ltd reported Q1 FY27 financial results with a 41.5% YoY increase in total income to Rs. 252.2 crore, a 27.3% YoY increase in EBITDA to Rs. 44.1 crore, and a 26.6% YoY increase in PAT to Rs. 26.7 crore. The company also announced strategic initiatives including a proposed acquisition of up to 51% equity in GScale Energy Private Limited and a strategic investment in GL Hakko Co., Ltd., Japan.

Standard Engineering Technology Limited reported Q1 FY27 financial results with a 41.5% YoY increase in total income to Rs. 252.2 crore, 27.3% YoY increase in EBITDA to Rs. 44.1 crore, and 26.6% YoY increase in PAT to Rs. 26.7 crore. The company also announced strategic initiatives, including a proposed acquisition of up to 51% equity in GScale Energy Private Limited and a strategic investment in GL Hakko Co., Ltd., Japan.

Deepak Fertilisers & Petrochemicals Corporation Ltd's Q1 FY 2027 earnings conference call transcript is available on the company's website, with management discussing a 65% jump in operating EBITDA and doubling of PAT, despite volatility from the Middle East war. The company's integrated value chain and alignment with India's growth story are highlighted as key strengths.

Edelweiss Financial Services Ltd has released a business update on EAAA Alternatives, a subsidiary, highlighting a large and scalable opportunity in the Indian Alternatives market. The update projects a 2.6x surge in Alternatives AUM from $276 billion in 2016 to $211 billion by 2030, with a dominant share of over 50% of the entire Indian Alts market. The update also emphasizes the growing pool of domestic investors, with HNIs and UHNIs projected to grow at 9.6% and 15.8% CAGR respectively by 2027.

Edelweiss Financial Services Ltd announced a business update on EAAA Alternatives, a subsidiary of the company, highlighting the opportunities in the Indian Alternatives market, with a projected AUM of $211 bn by 2030 and a CAGR of 18%.

Procter & Gamble Health Ltd has announced its unaudited financial results for the quarter ended June 30, 2026, with sales up 7% and PAT up 45% compared to the same period last year.

Edelweiss Financial Services Limited has informed the Exchange regarding 'Business Updates in US Dollars' for its subsidiary EAAA India Alternatives Limited, highlighting a large and scalable opportunity in the Indian alternatives market, with a projected AUM of $166 bn by 2030 and a 2.6x surge from 2016 levels.

Procter & Gamble Health Limited has announced its financial results for the first quarter ended June 30, 2026, with sales up 7% and Profit After Tax (PAT) up 45%.

Procter & Gamble Health Ltd has announced its unaudited financial results for the quarter ended June 30, 2026, with a profit before tax of ₹12,912 lakhs, a 9.3% increase from the previous quarter's ₹11,811 lakhs. The company's total income was ₹37,459 lakhs, a 0.4% increase from the previous quarter's ₹37,045 lakhs. Expenses for the quarter were ₹27,027 lakhs, a 12.1% decrease from the previous quarter's ₹30,727 lakhs.

Edelweiss Financial Services Limited has informed the Exchange regarding 'Business Update' on EAAA Alternatives, a subsidiary of the Company, highlighting the Alternatives Opportunity in India, with a Large & Scalable Opportunity, Yield & Income Generating Alternatives Outpacing the Industry, and Backed by a Deepening Pool of Domestic Investors.

Edelweiss Financial Services Limited has released its earnings update for the quarter ended June 30, 2026, showing a 83% YoY growth in consolidated PAT to $13 Mn, with robust growth in alternative asset management fee-paying AUM and mutual fund equity AUM. The company's total customer reach increased to 14 Mn, up 30% YoY, and customer assets reached $30 Bn, up 23% YoY. The company's balance sheet remains resilient with well-capitalized businesses and a decline in corporate net debt by 10% YoY.

Emcure Pharmaceuticals Ltd has announced its unaudited financial results for the quarter ended June 30, 2026, showing a strong all-round performance with increased revenue, EBITDA, and PAT. The company has also announced key leadership changes, including the appointment of Mr. Satish Mehta as Chairman and Mr. Samit Mehta as COO, and the elevation of Gennova Biopharmaceuticals to a wholly-owned subsidiary.

Edelweiss Financial Services Ltd has announced its earnings update for the first quarter ended June 30, 2026, with a consolidated PAT of $13 Mn, a 83% YoY growth. The company's Alternative Asset Management Fee Paying AUM grew by 27% YoY to $5,140 Mn, and Mutual Fund Equity AUM increased by 32% YoY to $10,148 Mn. The company's total customer reach increased to 14 Mn, up 30% YoY, and customer assets at $30 Bn, up 23% YoY.

Procter & Gamble Health Limited has submitted its unaudited financial results for the quarter ended June 30, 2026, with the company's board of directors approving the results. The results show a profit before exceptional items and tax of ₹97,31, ₹13,321, and ₹11,181 for the current, previous, and corresponding quarters, respectively.

Fredun Pharmaceuticals Ltd has announced its unaudited financial results for Q1 FY27, with revenue jumping 90%, EBITDA surging 93%, and profit rising 95% YoY. The company has also allotted 1.10 crore Bonus Equity Shares in a 2:1 ratio to eligible shareholders.

Edelweiss Financial Services Limited has announced its earnings update for the first quarter ended June 30, 2026, with a consolidated PAT of INR 122 Cr, a 83% YoY growth. The company's alternative asset management fee-paying AUM grew by 27% YoY to INR 48,623 Cr, and mutual fund equity AUM increased by 32% YoY to INR 96,000 Cr. The company's total customer reach increased to 14 Mn, up 30% YoY, and customer assets at INR 2.8 Tn, up 23% YoY.

Emcure Pharmaceuticals Limited has informed the Exchange about Investor Presentation, which includes unaudited financial results for Q1FY27. The presentation highlights a strong all-round performance with increased revenue and growth in the International business (58% contribution). Domestic revenue growth is at 10.2%, with productivity gains and operating leverage improving EBITDA margin by 50 bps and PAT margin by 110 bps. The company has also announced key appointments and restructuring of its leadership and operations.